No Increase in Cardiovascular Events with JAK Inhibitors in IBD Patients UMKC researchers have compared the use of JAK inhibitors versus tumor necrosis factor (TNF) blockers in inflammatory bowel disease (IBD) patients, but failed to see an increase in major adverse… https://t.co/XY0UVDTAI6 https://t.co/b09FB3niNP

⭐️Top tip from Dr Laura Carbone: 🦴Rule out hypophosphatasia before starting bisphosphonate or denosumab in patients with low ALP #ACR24 @RheumNow

Risk for atypical femoral fracture: 🚨Asian race - 4-6x higher risk Duration of use is greater risk than older age Higher risk when given for osteoporosis than cancer treatment - Compare: osteonecrosis of jaw more common with cancer Rx #ACR24 Review Course @RheumNow https://t.co/V8cD5QWNGp

• https://x.com/ericdeinmd/status/1857473638892441852/photo/1

🔍 Safety of a JAKi Across 15,000 Patient-Years of Data Now in the RheumNow poster hall: Safety outcomes with a JAKi from 11 Phase 3 trials in adult patients with RA, PsA, AS, and nr-axSpA. Sponsored by AbbVie US Medical Affairs. https://t.co/yeif38wKIY https://t.co/earZnqZLSI

• Safety of a JAKi Across 15,000 Patient-Years of Data | RheumNow